Reviews/Statins/Statin absolute benefit is small in low cardiovascular risk primary prevention patients
· ST-PRI-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This corpus asks not whether statins work in lower-risk people without prior heart disease, but how much they help in absolute terms. In the one study that cleanly isolated a low-risk group, the extra people spared death or major cardiovascular disease over a decade was under one in a hundred [1]. Other datasets point the same way: the number of people you must treat to prevent one event roughly doubles as predicted risk falls [17], and the absolute gain is larger in higher-risk subgroups than lower-risk ones [10]. People with little coronary calcium had very few events either way, so had little to gain [4]. The relative effect of statins stays roughly constant across risk levels, but because low-risk people have few events to begin with, the absolute benefit they can capture is small.
The one study with a pre-specified low predicted-risk stratum reports 10-year absolute risk differences of -0.53% for all-cause mortality and -0.83% for major cardiovascular disease [1], both under one percent. A pooled primary-prevention analysis shows the 5-year number needed to treat rising from 14 to 37 for those with estimated Framingham risk greater or less than 10% [17]. Across three trials the absolute risk reduction was 3.6% in the high genetic-risk group versus 1.3% in all others [10]. Low coronary calcium (<100) was associated with a low 10-year event rate (<1 per 100 person-years) and subjects who 'might not benefit from statin therapy within 5 years' [4]. Hypertensive primary-care patients without diabetes or prior CVD showed modest absolute event counts over about four years [12]. The contested point: The division is over whether 'small' understates a real and statistically significant benefit: the cleanest low-risk estimate [1] has confidence intervals that exclude zero and concludes benefit occurred across the full spectrum of predicted risk. Its magnitude is also observational rather than RCT-grade, while the surviving low-LDL RCT data [16][17] come from an elevated-CRP population rather than a genuinely low-risk one.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim's cleanest support [1] still found a statistically significant benefit in the low-risk stratum (CIs exclude zero) and concludes benefit occurred 'across the full spectrum of predicted cardiovascular risk' — 'small' must not be read as 'absent'.
The single clean low-risk absolute estimate [1] is observational (target-trial emulation); its stated limitation is unmeasured confounding and underascertainment of some outcomes, so the magnitude is not RCT-grade.
Where it remains uncertain. That low-risk benefit is still statistically significant and 'across the full spectrum of predicted cardiovascular risk' [1], so 'small' should not be read as 'absent'.
Aleatory
The low-risk absolute risk differences are near the limit of detectability, with confidence intervals approaching zero (-0.90% to -0.08% for mortality) [1]; chance variation in a few events moves the estimate materially.
Epistemic
Only one paper [1] reports a pre-specified low (<10%) risk stratum with absolute risk differences; the magnitude at low risk rests on one dataset.
Inferential
The corpus never sets a threshold for what counts as small absolute benefit, so the judgement is applied rather than measured.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Directly quantifies a small absolute benefit (under 1% over 10 years) in a pre-specified low-risk (<10%) primary-prevention stratum.
“In the low-risk stratum, RDs and RRs were -0.53% (95% CI, -0.90% to -0.08%) and 0.80 (95% CI, 0.67 to 0.97), respectively, for all-cause mortality and -0.83% (95% CI, -1.28% to -0.34%) and 0.78 (95% CI, 0.66 to 0.91), respectively, for major CVD.”
Panel auditInternal validity: medium · scope of inference: Adults with type 2 diabetes and no prior CVD in UK primary care, stratified by predicted 10-year CV risk.Key limitations: observational, unmeasured confounding · T2DM-only population · outcome underascertainment
Supports minimal absolute benefit in the lowest-risk (low coronary-calcium) subgroup.
“a small number of statin eligible subjects with low CAC might not benefit from statin therapy within 5 years”
Panel auditInternal validity: low · scope of inference: Asymptomatic individuals with elevated CAC, re-stratified by guideline statin eligibility and CAC category.Key limitations: post-hoc subgroup · pairwise contrast untested · CAC-enriched enrolment
Independent demonstration that absolute benefit scales down with lower baseline risk.
“Across all 3 studies, the absolute risk reduction with statin therapy was 3.6% (95% CI, 2.0-5.1) among those in the high genetic risk group and 1.3% (95% CI, 0.6-1.9) in all others.”
Panel auditInternal validity: medium · scope of inference: Primary-prevention trial participants stratified by polygenic coronary risk score.Key limitations: genetic not clinical risk stratifier · post-hoc subgroups · mixed trial/cohort data
The stratifier is advanced age, not low cardiovascular risk, so the reported risk reductions do not speak to the magnitude of benefit specifically in low-risk patients.
Panel auditInternal validity: medium · scope of inference: Adults aged 75 and older meeting statin indications, without preexisting CVD.Key limitations: age not CV-risk stratification · observational confounding · wide per-protocol CIs
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, multi-dataset support for a small absolute benefit at low risk, but the cleanest low-risk estimate is a single observational study and 'small' is partly a qualitative judgement, so it falls short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No RCT-grade low-risk absolute estimate. The only clean low-risk absolute risk difference [1] is observational; the verdict's magnitude would be far firmer with randomised data in the same stratum. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A primary-prevention RCT or individual-patient-data meta-analysis pre-specifying a low (<10%) predicted-risk stratum and reporting absolute risk differences, not just relative risk.
Open question: What is the RCT-grade absolute benefit of statins in a genuinely low-risk primary-prevention population? Why it is still open: The corpus's clean low-risk absolute estimate [1] is observational and the randomised data [16][17] come from an elevated-hsCRP cohort rather than a low-risk one.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19